Cancer Drugs– tag –
-
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 5 – The Rise of China and Asian ADC Players: How the Global Map Is Being Redrawn and Where Japan Can Stand
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examin In Part 1 of this series, we explored why the ADC land grab is happening now and how A... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 4 – How to Read ADC Deals: M&A, Licensing, Co-development, and CDMO Agreements
In Part 1 of this series, we looked at why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we exami In Part 1 of this series, we looked at why the ADC land grab is happening now and how ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 3 – Patent Cliffs and ADCs: Why Big Pharma Wants ADCs as Growth Engines for the Next Decade
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit within the broader landscape of cancer therapies, highli In Part 1 of this series, we explored why the ADC land grab is happening now and how A... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 2 – ADC Structure and Generational Shift: What “Second- and Third-generation” ADCs Really Mean After Enhertu
In Part 1 of this series, we asked why the ADC land grab is happening now, and we positioned ADCs within the broader landscape of cancer therapies, di In Part 1 of this series, we asked why the ADC land grab is happening now, and we posi... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 1 – Why is There an ADC Land Grab Now? Introducing ADC’s Place in Cancer Therapy
Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncology and biopharma news. Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncolo... -
Aging and Cancer Expert Series – Part 10 Future Directions: Where Might Aging × Cancer Research Go in the Next 10–20 Years?
Introduction: A Map of Aging × Cancer Is Starting to Emerge In this final article of the Expert Series, we step back to ask: In this final article of the Expert Series, we step back to ask: What you will learn Introduction: A Map of Agin... -
Aging and Cancer Expert Series – Part 9 Modeling Aging and Cancer: From Cells and Organoids to Mice and Human Cohorts
Introduction: Why “Young” Models Struggle to Capture “Old” Cancer Throughout this Expert Series we have discussed: Throughout this Expert Series we have discussed: What you will learn Introduction: Why “Young” Models Struggle to Capture ... -
Aging and Cancer Expert Series – Part 8 Geriatric Oncology in Practice: Bringing Aging Biology into Cancer Care
Introduction: The Gap Between Aging Biology and Everyday Oncology In earlier parts of this Expert Series, we have explored: In earlier parts of this Expert Series, we have explored: What you will learn Introduction: The Gap Between Aging... -
Aging and Cancer Expert Series – Part 7 Diet, Exercise, Environment, and Geography: External Drivers of Aging × Cancer Risk
Introduction: Adding Lifestyle and Environment to the Genetics–Aging Framework In previous parts of this Expert Series, we focused primarily on “internal” factors: In previous parts of this Expert Series, we focused primarily on “interna... -
Aging and Cancer Expert Series – Part 6 Does Aging Always Promote Cancer? Insights from KRAS-Driven Lung Cancer
Introduction: Questioning the Dogma that “Aging = More Cancer” In previous parts of this Expert Series, we have discussed: In previous parts of this Expert Series, we have discussed: What you will learn Introduction: Questioning the Dogm... -
Aging and Cancer Expert Series – Part 4 Reproductive Aging and Women’s Cancers: Linking Ovary, Uterus, and Breast Through Hormones and Molecular Networks
Introduction: Reproductive Aging as a Hub Between Women’s Aging and Cancer In Parts 1–3 of the Expert Series, we discussed: In Parts 1–3 of the Expert Series, we discussed: What you will learn Introduction: Reproductive Aging as a Hub Be... -
Aging and Cancer Expert Series – Part 3 Cancer as a Driver of Systemic Aging: Immune, Tissue, and Treatment-Related Pathways
Introduction: Beyond “Aging → Cancer” to “Cancer → Aging” In the Introductory and earlier Expert Series articles, we mainly focused on the direction: In the Introductory and earlier Expert Series articles, we mainly focused on the direct... -
Aging and Cancer Expert Series – Part 2 Tissue-Specific Aging Profiles and Genetic Background: Why Cancer Prefers Certain Organs
Introduction: Aging Is Not Uniform Across the Body In Part 1 of the Expert Series, we focused on “making aging visible” through epigenetic clocks, single-cell analyses, and image-based metrics. In Part 1 of the Expert Series, we focused ... -
Oncology Drug Approval News Flash: FDA grants regular approval to rucaparib for BRCAm mCRPC and approves subcutaneous amivantamab and hyaluronidase-lpuj
FDA approval summary On December 17, 2025, the U.S. Food and Drug Administration (FDA) granted regular approval to rucaparib (Rubraca, pharmaand GmbH) for adult patients with metastatic castration-resistant prostate cancer (mCRPC) associ... -
Oncology Drug Approval News Flash: Fam-trastuzumab deruxtecan-nxki plus pertuzumab approved as first-line therapy for unresectable or metastatic HER2-positive breast cancer
FDA approval summary On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with un... -
From Beginner to Expert | Aging and Cancer Introductory Series – Part 5 Lifestyle and Environmental Factors in Aging and Cancer: What Can We Change, and What Is Hard to Change?
Introduction: Deconstructing Risk Factors In Parts 1–4 of this series, we explored aging and cancer from several angles: In Parts 1–4 of this series, we explored aging and cancer from several angles: What you will learn Introduction: Dec... -
Oncology Drug Approval News Flash: Niraparib plus abiraterone acetate and prednisone approved for BRCA2-mutated metastatic castration-sensitive prostate cancer
FDA approval summary On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adult patients with deleterious or suspected deleteriou... -
Recent ADC Landscape Update Series, Part 3: Merck–Daiichi’s CDH6 ADC R-DXd and DLL3 ADC SHR-4849 – The Next Wave in Ovarian Cancer and SCLC
In Part 3 of this series, we focus on two “second-wave” ADC programs that have attracted considerable attention over the past few months: raludot In Part 3 of this series, we focus on two “second-wave” ADC programs that have at... -
Recent ADC Landscape Update Series, Part 2: Enhertu in Early HER2-Positive Breast Cancer – What DESTINY-Breast05 and 11 Mean for Future Standards of Care
In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-based ADC from AstraZeneca and Daiichi Sankyo that has already tr In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-b... -
Recent ADC Landscape Update Series, Part 1: AstraZeneca’s Post-Enhertu Strategy – In-house ADCs, Radiopharma and Cell Therapy to Redefine Oncology
Around 2025, oncology is entering a new phase in which antibody–drug conjugates (ADCs) sit at the center of a much broader competition for the “next decade” of cancer care. Around 2025, oncology is entering a new phase in which antibody–...
